Table II.
PD-L1 expression in TCs and ICs.
| PD-L1 expression in TCs | PD-L1 expression in ICs | ||||
|---|---|---|---|---|---|
| Subtype | No. | Negative, n (%) | Positivea, n (%) | Negative, n (%) | Positivea, n (%) |
| HR+HER2− | 45 | 42 (93.3) | 3 (6.7) | 38 (84.4) | 7 (15.6) |
| HR+HER2+ | 6 | 6 (100.0) | 0 (0) | 4 (66.7) | 2 (33.3) |
| HR−HER2+ | 3 | 2 (66.7) | 1 (33.3) | 1 (33.3) | 2 (66.7) |
| TN | 19 | 11 (57.9) | 8 (42.1) | 8 (42.1) | 11 (57.9) |
| All | 73 | 61 (83.6) | 12 (16.4) | 51 (69.9) | 22 (30.1) |
a
PD-L1 expression was evaluated using SP142 antibody, and judged using a 1% cutoff. TCs, tumor cells; ICs, immune cells; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TN, triple-negative.